About QYUNS-B Company

Established in 2015, Quanxin Biotech is a late-clinical biomedical enterprise focusing on biotherapy for autoimmune and allergic diseases. It has a completely self-developed drug pipeline and mature commercial-grade internal production capacity. Quanxin Biotech adheres to the development concept of “innovating for the largest number of patients” and strives to solve the problems of drug accessibility and affordability in areas of concern. Based on complete independent innovation capabilities, the company has now formed a product pipeline with multiple innovative varieties. The indications cover the four major skin, respiratory, digestive, and rheumatic diseases such as psoriasis, atopic dermatitis, ankylosing spondylitis, inflammatory bowel disease, systemic lupus erythematosus, and asthma. It has become one of the companies with the most comprehensive biopharmaceutical pipeline layout in the field of autoimmune and allergic diseases in China and the most advanced overall development progress. The company continuously strengthens development certainty through a forward-looking layout on the production side and sales side. Currently, Quanxin Biotech has owned and applied for more than 60 domestic and foreign patents. It is a national high-tech enterprise, and has also been recognized as a potential unicorn enterprise by the Jiangsu Productivity Promotion Center.